Hanmi Pharmaceutical Co. Ltd (Hanmi)(KRX:128940), a Korea-based pharmaceutical company, today announced that it has entered into an exclusive development and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of Hanmi’s pan-RAF inhibitor, HM95573 which is currently in Phase I clinical development.
Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commercialize HM95573. Hanmi will receive an initial upfront payment of $80 million and is eligible to receive payments based on achievement of certain predetermined development, regulatory and commercialization milestones totaling up to $830 million. In addition, Hanmi is eligible to receive tiered double digit royalties on sales of certain products resulting from the license agreement. Full financial terms have not been disclosed.
The completion of this agreement is subject to US customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, which is expected to occur during the fourth quarter of 2016.
“We are pleased to collaborate with Genentech, which has significant expertise in the field of oncology,” said Dr. Gwan Sun Lee, CEO/President of Hanmi Pharmaceutical. “We are excited about the potential this license agreement with Genentech will bring to the development of HM95573 and the potential benefit this may offer to cancer patients worldwide.”
“This collaboration demonstrates our commitment to bring the best science in the world to Genentech with the ultimate goal of developing life-changing therapies for people with cancer,” said James Sabry, M.D., Ph.D., Senior Vice President and Global Head of Genentech Partnering. “We are excited to partner with Hanmi and leverage their scientific insights to develop novel therapies that target the MAPK pathway.”
Pharmaceutical Co., Ltd.
Hanmi Pharm. Co., Ltd. is a Korea-based pharmaceutical company, fully integrated with strong focus in R&D which is strategically designed in 3 major fields: 1) Biologics: LAPSCOVERY platform applied long-acting pipelines. Key targeting areas are diabetes and obesity; 2) NCE: Mainly oncology and auto-immune disease targeted pipelines; and 3) Fixed-dose combination programs. The company has worked closely with global partners on various co-developments and collaborations. Hanmi continues to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.
RAF kinases, consisted of three subtypes (A-RAF, B-RAF, C-RAF), are one of the mitogen activated protein kinases (MAP Kinase) that transduce signals in cells, and especially B-RAF and C-RAF are known to be associated with various cancers.
This press release includes forward-looking statements about the development and license agreement between Hanmi Pharmaceutical Co., Ltd. and Genentech and reflects Hanmi’s current beliefs. While Hanmi believes the forward-looking statements contained in this press releases are accurate, those statements are subject to risks and uncertainties that could cause actual outcomes to vary materially from the outcomes reference in the forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005579/en/Business Wire
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.